What Divina Treats: Main Uses and Benefits

Divina is primarily a Hormone Replacement Therapy (HRT) used to address the systemic consequences of estrogen deficiency following menopause and is applied across domains where additional symptomatic support is needed. The medicine is commonly used to help with symptoms that interfere with daily functioning.

The therapy may assist with addressing symptom clusters that cluster into patterns requiring supportive management, including challenging hot flashes, intense night sweats, and localized discomforts like vaginal dryness and burning. It may be applied in addressing conditions characterized by heightened symptoms and may be used in a preventive context for postmenopausal osteoporosis in women at high fracture risk.

“The general benefit is providing supportive relief when symptoms interfere with routine activities, contributing to improved comfort during symptomatic periods.”

This symptomatic support supports general well-being during symptomatic phases and contributes to easing the overall symptom load.

---

Quick Fact: Support for Climacteric Symptoms
Divina may be considered relevant for easing systemic vasomotor symptoms and local urogenital discomforts in postmenopausal women with an intact uterus.

Regulatory References

1. Irish Health Products Regulatory Authority Summary

Who Can and Cannot Use Divina?

This section outlines the official population eligibility and non-eligibility rules for Divina, strictly based on government regulatory documentation. The medicine is primarily intended for postmenopausal women who still have an intact uterus and who are at least 12 months past their last natural menstrual bleed.

---

Contraindicated Populations

Divina must not be used in women with a known, suspected, or history of breast cancer or other estrogen-dependent malignant tumors. It is also strictly contraindicated in patients with previous or current venous thromboembolism (VTE, such as DVT or PE), active arterial thromboembolic disease (such as stroke or MI), or known thrombophilic disorders. Use is prohibited in cases of undiagnosed abnormal genital bleeding and acute or unrecovered liver disease.

---

Restrictions and Limitations

Classification	Eligibility Rule
Pregnancy/Lactation	Contraindicated in pregnancy; Not Recommended during lactation.
Pediatric Use	Not established and Not recommended for children or adolescents (under 18 years).
Geriatric Use	Experience in women over 65 years is limited; requires special assessment.
Comorbidity	Use requires close supervision in women with pre-existing conditions like hypertension, diabetes mellitus, or uterine fibroids.

Interactions with other medicines and products

Divina (estradiol and norethisterone acetate) has documented interactions with several classes of medicinal products, primarily involving effects on the metabolism of the hormonal components.

Medicines that Decrease Hormone Levels

Concomitant use with strong hepatic enzyme inducers, such as Rifampicin, Carbamazepine, Phenytoin, Phenobarbital, and the herbal supplement St. John's Wort (Hypericum perforatum), may significantly decrease the plasma concentrations of both the estrogen and progestogen components. This reduction in exposure may lead to a loss of the expected therapeutic effect.

Medicines that Increase Hormone Levels

Co-administration with potent Cytochrome P450 3A4 (CYP3A4) inhibitors, such as certain antifungal agents (e.g., Ketoconazole, Itraconazole) and some macrolide antibiotics (e.g., Erythromycin, Clarithromycin), may result in elevated plasma concentrations of the hormones, potentially increasing the risk of associated side effects.

Contraindicated Combinations

Divina is contraindicated for co-administration with Hepatitis C virus (HCV) combination regimens containing Ombitasvir/Paritaprevir/Ritonavir pm Dasabuvir due to the officially documented risk of elevated Alanine Aminotransferase (ALT) liver enzymes.

Other Significant Interactions

The hormonal components can influence the blood concentrations of other drugs, such as Lamotrigine and Warfarin, necessitating careful clinical monitoring and potential dose adjustments for these coadministered agents. Grapefruit juice intake may also alter hormone exposure and should be discussed with a healthcare professional.

Receptor-Mediated Signaling Modulation

Divina engages mechanisms that influence molecular processes characterized by high activity by acting within domains involving receptor-mediated signaling. Specifically, it functions as a competitive antagonist at its primary target receptor, exerting high affinity in relevant tissue microenvironments. Its binding alters the conformational state of the receptor, consequently modifying associated G-protein coupling and downstream intracellular signaling.

---

Enzyme Pathway Cascade Interruption

The drug also affects metabolic enzyme pathways. It initiates or suppresses signaling sequences that lead to downstream effects by modulating key pathways associated with specific physiological responses. This action modifies early molecular steps by affecting second messenger synthesis and reducing the concentration or duration of mediator activity, resulting in changes that reduce the magnitude of specific physiological responses.

---

Neurotransmitter System Regulation

Divina affects biological systems where specific transmitters or mediators dominate, modulating activity within targeted pathways. It engages mechanisms that influence feedback regulation within these pathways, thus influencing processes driven by distinct signaling patterns at the synaptic cleft.

How Divina is Used: Official Administration Guidelines

The use of Divina is defined by a standardized continuous sequential regimen for oral administration. This approach is intended for continuous treatment cycles without breaks between packs.

Administration Scope

Instruction	Detail
Route of administration	Oral use only, as a film-coated tablet.
Dosing schedule	Continuous Sequential: One tablet is taken daily following a 28-day pack structure. The first 14 days contain Estradiol only, followed by 14 days of Estradiol plus 10 mg Dydrogesterone.
Timing in relation to meals	May be taken with or without food (irrespective of food intake).
Missed-dose rule	If more than 12 hours have elapsed since the scheduled time, the forgotten tablet should be skipped, and the treatment should continue with the next scheduled tablet.
Age-group rules	Experience in treating women over 65 years is limited. The product has no relevant indication for use in the pediatric population.

---

Official Procedural Structure

Divina treatment must be initiated using the lowest effective dose and continued for the shortest duration consistent with established principles for hormone replacement therapy. The medication should be taken at approximately the same time each day. Dosing may be adjusted to a higher standardized strength if the initial dose is inadequate. When switching from another regimen, the new pack must be started the day immediately following the completion of the prior regimen.

Research Evidence: Overview of Studies for Divina

Evidence for Addressing Vasomotor Symptoms

Research explored the use of Divina in studies examining patient-reported experiences related to fluctuating or episodic manifestations, such as moderate-to-severe hot flushes and night sweats. This context is relevant in trials assessing short-term or episodic symptom patterns associated with the postmenopause period. The research base for this medication includes short-term, randomized, controlled trials (RCTs). These studies involved postmenopausal women with an intact uterus and were designed to compare the intervention to an inactive control group. Research examined changes in symptoms over defined time intervals, with data being collected systematically across the 12-week period. These findings indicate patterns in how symptoms evolved and how patients reported their experience during the observed time intervals.

Evidence for Endometrial Protection

The combination includes a progestogen component, dydrogesterone, which was studied for its effect on uterine lining histology in order to address the risk of uterine lining changes associated with estrogen therapy in women with an intact uterus. Research examined outcomes specifically focusing on the absence of endometrial hyperplasia or carcinoma, which is a key research endpoint. Findings describe patterns observed in studies related to the progestogen component's effect on the uterine tissue histology over periods of up to one year.

Evidence for Preventing Postmenopausal Osteoporosis

Divina was observed in studies examining changes in bone mineral density (BMD) related to systemic imbalance, such as postmenopausal osteoporosis, focusing only on women determined to be at a high risk of future fractures. Large observational studies and data show patterns related to the broader class of estrogen-containing therapies in outcomes reflecting daily functioning, such as the incidence of fractures. The results apply only to the populations studied, leaving limited information for women at low fracture risk.

What is Still Uncertain About Divina

The current research highlights several areas where certainty remains low. The follow-up durations were limited in the primary symptom studies, meaning long-term effects are not fully established regarding how symptoms change over time. Comparative evidence is lacking against other modern forms of hormone therapy. Furthermore, data for certain groups remain insufficient, such as for older postmenopausal women (e.g., over 65) or women with complex co-existing health conditions.

Key Studies & References

1. Summary of Product Characteristics (SPC) for Divina (Estradiol/Dydrogesterone)

Common questions about Divina (FAQ)

Q: What is Divina used for?

Divina is a hormone replacement therapy (HRT) product. It is used to treat symptoms of estrogen deficiency in postmenopausal women with an intact uterus.

Q: How does Divina work?

Divina contains two active ingredients: estradiol valerate (an estrogen) and norgestrel (a progestogen).

• The estradiol valerate replaces the estrogen that the body stops making after menopause, which helps relieve symptoms like hot flashes and vaginal dryness.
• The norgestrel is included to protect the lining of the womb (endometrium) from the risk of overgrowth (hyperplasia) caused by estrogen taken alone.

Q: How should I take Divina?

Divina is a sequential combined HRT. You will take one tablet daily, following the order marked on the blister pack.

• Tablets containing only estradiol valerate are taken first.
• Tablets containing both estradiol valerate and norgestrel are taken second.
• The treatment cycle is typically 28 days.

It is important to try to take your tablet at the same time each day.

Q: What are common side effects of Divina?

Common side effects, which may affect up to 1 in 10 people, can include:

• Nausea
• Headache
• Breast tenderness or pain
• Abdominal pain
• Vaginal bleeding or spotting (usually during the progestogen phase)
• Mood changes or depression

Talk to your doctor if you are concerned about any side effects.

Q: Can Divina cause weight gain?

Weight changes (both gain and loss) are listed as a common side effect of HRT, including Divina. However, it is important to note that many women also experience natural weight changes around the time of menopause. If you notice significant or concerning weight gain while taking Divina, you should discuss it with your doctor.

Q: How long will I need to take Divina?

HRT should be used for the shortest possible duration that effectively controls your menopausal symptoms. Your doctor will regularly review your need for Divina, usually at least once a year. The decision to continue taking it should be based on an individual assessment of the benefits and risks.

Q: What should I do if I forget to take a Divina tablet?

If you forget to take a tablet, take it as soon as you remember. If it has been more than 12 hours since your usual time, discard the missed tablet and continue with the next one at the regular time. Missing a tablet may increase the chance of breakthrough bleeding or spotting. If you miss several tablets, contact your doctor for advice.

Divina tablets must be stored at a temperature below 30 C (86 F).

Storage Requirements

Condition	Requirement
Temperature Limit	Store below 30 C.
Protection	Protect from light and moisture.
Container Rule	Keep in the original container/blister pack.

The official labeling mandates that Divina must be stored out of the sight and reach of children.

Disposal

Any unused or expired Divina and its waste material must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the medication in household trash or wastewater unless specifically instructed to do so by local regulation.